TCGA-50-6591-01A-11R-1755-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V1+0.470
- MITOTIC_SPINDLE+0.420
- MYC_TARGETS_V2+0.380
- WNT_BETA_CATENIN_SIGNALING+0.310
- DNA_REPAIR+0.280
- UV_RESPONSE_DN+0.240
- SPERMATOGENESIS+0.210
- TGF_BETA_SIGNALING+0.180
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.580
- IL6_JAK_STAT3_SIGNALING-0.580
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.580
- INFLAMMATORY_RESPONSE-0.520
- TNFA_SIGNALING_VIA_NFKB-0.480
- COMPLEMENT-0.450
- APOPTOSIS-0.410
- COAGULATION-0.400
- XENOBIOTIC_METABOLISM-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_N6N147BY | Embryonal tumors | — | 0.915 |
| 2 | f2c3b90a.7e75.4a2a.925e.29eb9a2acac2 | — | cohortA3 | 0.910 |
| 3 | ERR2208889 | — | — | 0.910 |
| 4 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.910 |
| 5 | BS_BVSW4GTG | medulloblastoma | — | 0.907 |
| 6 | BS_1AYRM596 | medulloblastoma | — | 0.906 |
| 7 | de19e3c1-3508-4c13-b2cf-7079ee934a55 | — | — | 0.905 |
| 8 | BS_5P1TN10Z | Embryonal tumors | — | 0.905 |
| 9 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.903 |
| 10 | 0edf46a2-3dfb-4bae-b642-281e05975bd1 | — | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |